|Bid||0.4300 x 3100|
|Ask||0.4379 x 2200|
|Day's range||0.3800 - 0.4400|
|52-week range||0.2800 - 7.0700|
|Beta (5Y monthly)||1.15|
|PE ratio (TTM)||N/A|
|Earnings date||07 Nov 2022 - 11 Nov 2022|
|Forward dividend & yield||N/A (N/A)|
|1y target est||1.33|
Endo (ENDP) delivered earnings and revenue surprises of 118.75% and 9.01%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Endo International plc (NASDAQ: ENDP) today reported financial results for the second-quarter ended June 30, 2022.
Paladin Labs Inc., a subsidiary of Endo International plc (NASDAQ: ENDP), announced today that Health Canada has accepted its New Drug Submission (NDS) for cenobamate tablets as an adjunctive therapy for the management of partial-onset seizures in adults with epilepsy who are not satisfactorily controlled with conventional therapy. A decision from Health Canada as to whether cenobamate tablets can be marketed and sold in Canada under this NDS is expected mid-2023.